中国医药出海提速，诚邀海外医疗资源方共建合作桥梁

在多重利好政策与市场红利驱动下，中国医药企业“出海”趋势愈发显著。2024年，中国医药工业百强企业虽然整体收入连续三年承压，但出口交货值实现逆势增长，同比增长达 9.4%，凸显国际化布局的强劲动能。

与此同时，创新驱动已成为头部企业增长核心动力。百强企业平均研发投入达到8.3亿元，13家企业研发强度超过15%，多项自主研发药物陆续获得国际授权与上市资质，标志着中国创新药正加速参与全球竞争。

政策层面，多部委释放利好信号，鼓励医药企业“走出去”，支持全球同步研发、注册和市场准入。工信部、国家药监局等主管部门均表态将持续优化外部营商环境，提升国际合作效率。

在此背景下，“出海第一站”平台面向全球征集具备医药行业资源的合作机构，合作方向包括但不限于：

• 医院集团与连锁诊所资源方
• 药品代理、进口商、渠道商
• 医疗器械/耗材分销商与服务商
• 药品注册咨询、合规顾问机构
• 跨境CRO、CDMO服务方
• 政府健康机构、医疗基金会与协会

我们将协助中国医药企业与全球优质资源方对接，推动创新药出海、渠道合作、市场准入、项目共建等合作落地。

📩 如果您拥有相关资源并希望与中国企业合作，请尽快联系我们，加入我们的全球合作网络。

China’s Pharmaceutical Industry Accelerates Global Expansion — Invitation to Overseas Medical Partners to Join Forces

Driven by favorable policies and growing market opportunities, Chinese pharmaceutical companies are rapidly expanding their global footprint. In 2024, despite the third consecutive year of revenue pressure among China’s Top 100 pharmaceutical manufacturers, export delivery value defied the trend with a year-on-year growth of 9.4%, underscoring strong momentum in international expansion.

At the same time, innovation has become the core growth engine for leading enterprises. The Top 100 companies recorded an average R&D investment of 830 million RMB, with 13 companies allocating over 15% of revenue to research. Several self-developed drugs have secured international licensing and market approvals, marking China's innovative pharmaceuticals as active contenders in the global arena.

On the policy front, multiple government ministries have issued positive signals encouraging pharmaceutical companies to “go global.” Authorities such as the Ministry of Industry and Information Technology and the National Medical Products Administration have expressed commitments to further optimize the business environment and enhance the efficiency of international collaboration.

Against this backdrop, our platform — “First Stop Overseas” — is now seeking global partners with resources in the healthcare and pharmaceutical sectors. Areas of cooperation include but are not limited to:

• Hospital groups and clinic chains
• Pharmaceutical agents, importers, and distributors
• Medical device and consumables distributors and service providers
• Regulatory consulting and compliance advisory firms
• Cross-border CRO/CDMO service providers
• Governmental health institutions, medical foundations, and associations

We aim to connect top Chinese pharmaceutical companies with high-quality global partners, facilitating cooperation in innovative drug exports, channel building, market access, and joint project development.

📩 If you have relevant resources and are interested in collaborating with Chinese enterprises, contact us today to become part of our global partner network.

‍

‍

📩 欢迎合作与咨询，请添加微信

‍